Press releases
- Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
- Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
- Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
- Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
- Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
- Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼
Key statistics
As of last trade Silence Therapeutics PLC (SLNCF:PKC) traded at 8.00, -26.61% below its 52-week high of 10.90, set on Mar 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.00 |
---|---|
High | 8.00 |
Low | 8.00 |
Bid | -- |
Offer | -- |
Previous close | 8.00 |
Average volume | 697.00 |
---|---|
Shares outstanding | 46.50m |
Free float | 5.29m |
P/E (TTM) | -- |
Market cap | 1.05bn USD |
EPS (TTM) | -0.4836 USD |
Data delayed at least 15 minutes, as of Apr 15 2024 14:39 BST.
More ▼